Expertise in
9
conditions

Dr. Matthew J. Frigault

Oncology
Massachusetts General Hospital
55 Fruit St, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
Massachusetts General Hospital
55 Fruit St, 
Boston, MA 

Overview

Matthew Frigault is an Oncologist practicing medicine in Boston, Massachusetts.

Dr. Frigault is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, B-Cell Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 140 peer reviewed articles and participating in 9 clinical trials. Dr. Frigault is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MD

Hospital Affiliations

Massachusetts General Hospital
Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital District Physicians Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Massachusetts General Hospital
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: TriPRIL CAR T Cells, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2026
Intervention Type: Drug, Biological
Study Drugs: YTB323, Ibrutinib
Study Phase: Phase 1/Phase 2
Managed Access Programs for CTL019, Tisagenlecleucel
Managed Access Programs for CTL019, Tisagenlecleucel
Enrollment Status: Available
Publish Date: April 23, 2026
Intervention Type: Biological
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2026
Intervention Type: Biological
Study Drugs: Cyclophosphamide, Fludarabine, CD19-Positive CAR-T Cells
Study Phase: Phase 1/Phase 2
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Enrollment Status: Active_not_recruiting
Publish Date: February 11, 2026
Intervention Type: Drug
Study Drug: CART-ddBCMA
Study Phase: Phase 1
Pilot Study of Tisagenlecleucel, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Patients With Primary Central Nervous System Lymphoma
Pilot Study of Tisagenlecleucel, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Patients With Primary Central Nervous System Lymphoma
Enrollment Status: Completed
Publish Date: January 09, 2026
Intervention Type: Biological
Study Drug: Tisagenlecleucel
Study Phase: Phase 1
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 30, 2025
Intervention Type: Drug
Study Drug: Zelenoleucel
Study Phase: Phase 2
Radiation Therapy To Enhance CAR T Efficacy Early in Post-CAR T Cell Therapy Refractory Lymphoma: A Pilot Study
Radiation Therapy To Enhance CAR T Efficacy Early in Post-CAR T Cell Therapy Refractory Lymphoma: A Pilot Study
Enrollment Status: Terminated
Publish Date: September 24, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies
A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies
Enrollment Status: Completed
Publish Date: December 12, 2024
Intervention Type: Biological
Study Drug: CAR-37 T cells
Study Phase: Phase 1
View 8 Less Clinical Trials

140 Total Publications

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.
Journal: Thyroid : official journal of the American Thyroid Association
Published: May 12, 2026
Similar Doctors
Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

Massachusetts General Hospital

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeremy Abramson is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Abramson is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Aspiration, and Tissue Biopsy. Dr. Abramson is currently accepting new patients.

Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Office

55 Fruit St, 
Boston, MA 
 (0.1 miles away)
617-724-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edwin Choy is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Choy is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Synovial Sarcoma, and Osteosarcoma. Dr. Choy is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (2.7 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Davids is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Davids is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Tissue Biopsy. Dr. Davids is currently accepting new patients.

Frequently Asked Questions about Dr. Matthew J. Frigault

How do I make an appointment with Dr. Matthew J. Frigault?

You can book an appointment with Dr. Matthew J. Frigault by calling their office at 617-724-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Matthew J. Frigault a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthew J. Frigault is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthew J. Frigault specialize in?

While Dr. Matthew J. Frigault is a Oncology, they have specific expertise in Multiple Myeloma, B-Cell Lymphoma, and Non-Hodgkin Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Matthew J. Frigault participate in research or clinical trials?

Yes. Dr. Matthew J. Frigault has published 140 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Matthew J. Frigault's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthew J. Frigault accept my insurance?

Dr. Matthew J. Frigault accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-724-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Frigault's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile